Treatment of HER2 negative, luminal A in older adults with advanced breast cancer
V. Gebbia, M.R. Valerio
Vol.7 (2022), issue 1, pag. 94 - 99
| Received | 2/08/2021 |
| Accepted | 2/01/2022 |
| Published | 24/03/2022 |
| Review by | Double-blind |
| DOI | https://doi.org/10.48253/AGO27 |
ABSTRACT
Ageing is associated with increased number of comorbidities, poly- pharmacy, geriatric syndromes, as well as frailty. The large variety in characteristics within this population, together with the lack of evidence on the most suitable therapeutic approach and the limited data on older patients’ preferences, make treatment decision-mak- ing for these patients generally dif cult. Many of these pitfall stem from the underrepresentation of older women in clinical trials. Older adults have a high risk of experiencing adverse effects when ex- posed to systemic therapies. Age per se is not enough to establish best treatment and comprehensive geriatric assessment represents the adequate instrument to assess biological age and de ne a per- sonalized approach. The paper discuss data concerning the use of CDKI in older patients with metastatic breast cancer.